

## **Telmisartan & Olmesartan-based Combinations Improve Cardiovascular Biomarkers in Hypertensive Patients: RECENT EVIDENCE**

Jagodzinski A, et al. Clin Chem. 2017. [*Electronic Publication; Ahead of Print*]

- Hypertension is associated with a high rate of cardiovascular events and mortality. Cardiovascular biomarkers can predict long-term risk.
- In 481 hypertensive patients randomized to either 80-mg telmisartan + 5-mg amlodipine (TA) or 40-mg olmesartan + 12.5-mg hydrochlorothiazide (OH), significant reductions were observed in BP and markers of cardiovascular risk [high-sensitivity troponin I (hs-cTnI), high-sensitivity troponin T (hs-cTnT), B-type natriuretic peptide (BNP), and N-terminal-pro-BNP (NT-proBNP)] after 6 months.

*Telmisartan & Olmesartan-based Combinations Reduce BP  
and Improve Cardiovascular Risk Biomarkers in  
Hypertensive Patients.*